Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 15/20 | 0.43 |
| ▸ | GSK3B | P49841 | 6/20 | 0.41 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069317 | 0.82 | LRRK2 (0.40) | AURKAAURKBGSK3BSRCLRRK2 | |
| SCHEMBL14866664 | 0.81 | AURKA (0.44) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL12431000 | 0.80 | AURKA (0.42) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL5481449 | 0.79 | AURKA (0.54) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL4833901 | 0.73 | AURKA (0.49) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL12430988 | 0.73 | AURKA (0.54) | AURKAAURKBGSK3BSRC | |
| SCHEMBL5069055 | 0.71 | NEK1 (0.38) | AURKBGSK3BSRC | |
| SCHEMBL13663570 | 0.69 | JAK2 (0.46) | AURKAAURKBSRCLRRK2 | |
| SCHEMBL12431057 | 0.69 | ITK (0.41) | AURKAAURKBGSK3BSRCLRRK2 | |
| SCHEMBL4170159 | 0.68 | DYRK2 (0.39) | AURKAAURKBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | claimed |
| EP-1345929-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | BEBBINGTON DAVID (GB) | 2004-08-12 | — | — | US | claimed |
| US-6656939-B2 | Anticancer agents; autoimmune diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-02 | — | — | US | claimed |
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | claimed |
| US-20140187772-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-20140187772-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885AURKB 7/4885GSK3B 3/4885 |
| US-20140187772-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | AURKA 2/4885AURKB 5/4885GSK3B 4/4885 |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | AURKA 2/4885AURKB 5/4885GSK3B 4/4885 |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885AURKB 5/4885GSK3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.